MLL
AVTX icon

Moody Lynn & Lieberson’s Avalo Therapeutics AVTX Stock Holding History

Moody Lynn & Lieberson’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed -$5K – 218
2022
Q2 		$5K Hold
3
– – ﹤0.01% 219
2022
Q1 		$7K Hold
3
– – ﹤0.01% 228
2021
Q4 		$17K Buy
+3
New +$18K ﹤0.01% 235

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Moody Lynn & Lieberson's AVTX Position: Q3 2022 in Review

Moody Lynn & Lieberson sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 3 shares — an estimated $5K sold.

Moody Lynn & Lieberson first reported a position in AVTX in Q4 2021 and held it in 3 quarters. The position peaked at $17K in Q4 2021. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Moody Lynn & Lieberson reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 3 Avalo Therapeutics shares in Q3 2022, an estimated $5K.
  • Moody Lynn & Lieberson first reported a position in Avalo Therapeutics in Q4 2021 and held it in 3 quarters.
  • Moody Lynn & Lieberson's Avalo Therapeutics position peaked at $17K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Moody Lynn & Lieberson's 13F filing for Q3 2022, filed 26 Oct 2022.